




SUPPLEMENTARY FIGURES



Supplementary Figure 1. Subcellular localization of NOP14 in AsPC1 pancreatic cancer cell. Immunofluorescence analysis of NOP14 in AsPC1 pancreatic cancer cell (under a 1,000× objective). Blue, DAPI-labeled nuclei; green, FITC-labeled anti-NOP14 antibody; red, phalloidin-labeled cytoskeletal F-actin; merge, superimposition of the above three images.



Supplementary Figure 2. Impacts of NOP14 expression on pancreatic cancer cell proliferation. (A) Expression level of NOP14 in four pancreatic cancer cell lines as evaluated by Western blot analysis with standardized relative gray ratio. (B) Proliferation ability comparison of four pancreatic cancer cell lines. (C) NOP14 expression level after up- or downregulation of NOP14 in Mia PaCa2 cells, as determined by qRT-PCR. (D) NOP14 expression level after up- or downregulation of NOP14 in Mia PaCa2 cells, as determined by Western blot analysis. (E) Proliferation ability of Mia PaCa2 cells after up- or downregulation of NOP14. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.



Supplementary Figure 3. Correlation and prognostic analysis of downstream targeted genes with NOP14 and E2F4 in pancreatic cancer tissue from TCGA RNA seq data. (A) Scatter plots showing correlation analysis of downstream targeted genes with NOP14 and E2F4 in pancreatic cancer tissue from TCGA RNA seq data. **(B)** Kaplan-Meier survival analysis of gene E2F4 and AKT1 according to their expression in the TCGA pancreatic cancer dataset. The *P* value was obtained by Cox regression in R (version 3.6.3). **(C)** Transcriptional inhibition of target genes after downregulation of NOP14, as determined by qRT-PCR with Paired *t* test. **P* < 0.05, ***P* < 0.01.